IVCC, Scynexis sign agreement
The tie up aims to deliver a target list of compounds suitable for taking forward for further development. IVCC chief operating officer Tom McLean said this project joins
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.
Under the agreement, MANF-based therapeutic will be developed using Generex’s RapidMist technology in conjunction with oral-insulin spray technology Oral-lyn. Amarantus chief scientific officer John Commissiong said MANF’s profile